Evidence map›Paper›PMID 28072706›Full record

Trial reportMedicine2017

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.

Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Ho Gak Kim, Myung Hwan Noh, Sang Hyub Lee, Yong-Tae Kim, Hyo Jung Kim and 15 more

Open access · goldAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 6 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 6 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Chemotherapy and radiotherapy for advanced pancreatic cancer.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Chemotherapy and radiotherapy for advanced pancreatic cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  7. Review
  8. Article
  9. Review
  10. The efficacy and safety of gemcitabine-based combination therapyJournal of gastrointestinal oncology · 2022
    Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 1 institution in 4 countries.

Hee Seung LeeDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu Department of Internal Medicine, Dong-A University College of Medicine, Busan Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine Department of Internal Medicine, Korea University College of Medicine Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul Department of Internal Medicine, Keimyung University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine, Bucheon and Seoul Department of Internal Medicine, Pusan National University Hospital, Busan. Departments of Internal Medicine, Pusan National University Hospital, Yangsan Department of Internal Medicine, Digestive Disease Centre, Konkuk University School of Medicine, Seoul Departments of Internal Medicine, Hanyang University College of Medicine, Seoul Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan Department of Internal Medicine, The Catholic University of Korea College of Medicine, St. Mary's Hospital Biostatistics Collaboration Unit, Medical Research Center, Yonsei University College of Medicine, Seoul, Korea.
Moon Jae Chung
Jeong Youp Park
Seungmin Bang
Seung Woo Park
Ho Gak Kim
Myung Hwan Noh
Sang Hyub Lee
Yong-Tae Kim
Hyo Jung Kim
Chang Duck Kim
Dong Ki Lee
Kwang Bum Cho
Chang Min Cho
Jong Ho Moon
Dong Uk Kim
Dae Hwan Kang
Young Koog Cheon
Ho Soon Choi
Tae Hyeon Kim
Jae Kwang Kim
Jieun Moon
Hye Jung Shin
Si Young Song
Korean Society of Gastrointestinal Cancer
Apple (Israel) · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy.

methodsA total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients were randomly assigned to receive GemCap (oral capecitabine 1660 mg/m plus Gem 1000 mg/m by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break every 4 weeks) or Gem (by 30-minute intravenous infusion weekly for 3 weeks every 4 weeks).

resultsMedian overall survival (OS) time, the primary end point, was 10.3 and 7.5 months in the GemCap and Gem arms, respectively (P = 0.06). Progression-free survival was 6.2 and 5.3 months in the GemCap and Gem arms, respectively (P = 0.08). GemCap significantly improved overall response rate compared with Gem alone (43.7% vs 17.6%; P = 0.001). Overall frequency of grade 3 or 4 toxicities was similar in each group. Neutropenia was the most frequent grade 3 or 4 toxicity in both groups.

conclusionGemCap failed to improve OS at a statistically significant level compared to Gem treatment. This study showed a trend toward improved OS compared to Gem alone. GemCap and Gem both exhibited similar safety profiles.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCapecitabineDeoxycytidineDisease-Free SurvivalFemaleGemcitabineHumansMaleMiddle AgedNeutropeniaPancreatic NeoplasmsRepublic of KoreaCapecitabineDeoxycytidineGemcitabine

Identifiers

PMID28072706
PMCPMC5228666
OpenAlexW2570746401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.